File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2165/11596230-000000000-00000
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Individual Case Safety Reports and Useful Clinical Information
Title | Individual Case Safety Reports and Useful Clinical Information |
---|---|
Authors | |
Issue Date | 2011 |
Publisher | Adis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/ |
Citation | The 11th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 981-982, abstract no. PP163 How to Cite? |
Abstract | Objectives: Individual case safety reports (ICSRs) could be an important
source in giving further information to characterize the risk
situation and aid in the prevention, diagnosis, management and
treatment of adverse drug reactions (ADRs). The aim was to determine
whether and where on the ICSRs clinically useful information was
specified for rare ADRs in the paediatric population.
Methods: ICSR concerning rhabdomyolysis occurring during use of
antipsychotic medicines for patients up to 17 years of age were retrieved
from the WHO Global ICSR database, VigiBase. The original
case reports were requested and received from the national pharmacovigilance
centres. We focused on five areas of information specified
in a recent guideline for publishing ADRs.[1]
Results: Eighteen original cases with an age span from 5 to 17 years
were reviewed with the following outcomes.
Circumstances preceding the reaction: 9 reports included this information,
consisting primarily of abdominal, muscle and back pain. In eight
of these reports, the full account of the symptoms and sequence of
events were only found in the narratives.
Underlying risk factors for rhabdomyolysis: Recorded for four of five
patients in the narrative: seizures (n = 1), strenuous physical activity
(n = 2), diabetic ketoacidosis (n = 1), alcohol use (n = 1). Four patients
had Neuroleptic Malignant Syndrome (NMS) co-reported.
Physical examination and laboratory tests: All values for patient temperature
and laboratory values were given in free text. Elevated creatine
phosphokinase (CPK) or myoglobin values were recorded in
14 reports ranging from 1200 to 95 000 IU/L (CPK). Patient temperature
was specified for 5 patients, of whom 3 patients were also reported
to experience NMS.
Drug-reaction time-to-onset: 13 reports included information on the
duration from drug start to reaction onset, which ranged from 4 days
to 1.5 years. 9 reports included dates in the structured data, so that time
to onset could be calculated and in 4 reports the information was
specified in the narratives.
Treatment of the reaction: Apart from stopping the drug (n = 18) and
hospitalization (n = 16), other actions of treatment, such as forced intravenous
fluids or resolving spontaneously, was given for 5 cases in
the narrative.
Conclusions: This study showed that useful clinical information was
available to characterize the risk situation for these patients in this
subset of reports. This should be regarded in the context that ICSRs
are generally considered to be of poor quality. However, access to the
free text fields recorded by the reporter was crucial to capture this
information.
Reference
1. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting
adverse event reports for publication. Drug Saf 2007; 30 (5): 367-73 |
Description | Conference Theme: Next Stop: Istanbul — Bridging the Continents! Poster Presentation: no. PP163 |
Persistent Identifier | http://hdl.handle.net/10722/165611 |
ISSN | 2023 Impact Factor: 4.0 2023 SCImago Journal Rankings: 1.204 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Star, K | en_US |
dc.contributor.author | Almandil, NB | en_US |
dc.contributor.author | Wong, ICK | en_US |
dc.contributor.author | Strandell, J | en_US |
dc.contributor.author | Edwards, R | en_US |
dc.date.accessioned | 2012-09-20T08:21:14Z | - |
dc.date.available | 2012-09-20T08:21:14Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | The 11th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 981-982, abstract no. PP163 | en_US |
dc.identifier.issn | 0114-5916 | - |
dc.identifier.uri | http://hdl.handle.net/10722/165611 | - |
dc.description | Conference Theme: Next Stop: Istanbul — Bridging the Continents! | - |
dc.description | Poster Presentation: no. PP163 | - |
dc.description.abstract | Objectives: Individual case safety reports (ICSRs) could be an important source in giving further information to characterize the risk situation and aid in the prevention, diagnosis, management and treatment of adverse drug reactions (ADRs). The aim was to determine whether and where on the ICSRs clinically useful information was specified for rare ADRs in the paediatric population. Methods: ICSR concerning rhabdomyolysis occurring during use of antipsychotic medicines for patients up to 17 years of age were retrieved from the WHO Global ICSR database, VigiBase. The original case reports were requested and received from the national pharmacovigilance centres. We focused on five areas of information specified in a recent guideline for publishing ADRs.[1] Results: Eighteen original cases with an age span from 5 to 17 years were reviewed with the following outcomes. Circumstances preceding the reaction: 9 reports included this information, consisting primarily of abdominal, muscle and back pain. In eight of these reports, the full account of the symptoms and sequence of events were only found in the narratives. Underlying risk factors for rhabdomyolysis: Recorded for four of five patients in the narrative: seizures (n = 1), strenuous physical activity (n = 2), diabetic ketoacidosis (n = 1), alcohol use (n = 1). Four patients had Neuroleptic Malignant Syndrome (NMS) co-reported. Physical examination and laboratory tests: All values for patient temperature and laboratory values were given in free text. Elevated creatine phosphokinase (CPK) or myoglobin values were recorded in 14 reports ranging from 1200 to 95 000 IU/L (CPK). Patient temperature was specified for 5 patients, of whom 3 patients were also reported to experience NMS. Drug-reaction time-to-onset: 13 reports included information on the duration from drug start to reaction onset, which ranged from 4 days to 1.5 years. 9 reports included dates in the structured data, so that time to onset could be calculated and in 4 reports the information was specified in the narratives. Treatment of the reaction: Apart from stopping the drug (n = 18) and hospitalization (n = 16), other actions of treatment, such as forced intravenous fluids or resolving spontaneously, was given for 5 cases in the narrative. Conclusions: This study showed that useful clinical information was available to characterize the risk situation for these patients in this subset of reports. This should be regarded in the context that ICSRs are generally considered to be of poor quality. However, access to the free text fields recorded by the reporter was crucial to capture this information. Reference 1. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30 (5): 367-73 | - |
dc.language | eng | en_US |
dc.publisher | Adis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/ | - |
dc.relation.ispartof | Drug Safety | en_US |
dc.rights | The original publication is available at www.springerlink.com | - |
dc.title | Individual Case Safety Reports and Useful Clinical Information | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Wong, ICK: wongick@hku.hk | en_US |
dc.identifier.authority | Wong, ICK=rp01480 | en_US |
dc.identifier.doi | 10.2165/11596230-000000000-00000 | - |
dc.identifier.hkuros | 207505 | en_US |
dc.identifier.volume | 34 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | 981, abstract no. PP163 | - |
dc.identifier.epage | 982 | - |
dc.publisher.place | New Zealand | - |
dc.identifier.issnl | 0114-5916 | - |